The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2016 | Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany gives an overview of the KEYNOTE-024 trial results for non-small cell lung cancer (NSCLC) presented at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark. They KEYNOTE-024 trial is a Phase III trial of pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing NSCLC (NCT02142738). The assumption was that pembrolizumab will be superior to platinum-based chemotherapies in efficacy and this was observed in the trial. The primary endpoint was progression-free survival (PFS), which was in favor of pembrolizumab with a prolongation of median PFS from 6 months to 10.3 months. There was also an improvement in overall survival (OS) as well as an improvement in response. Further, the tolerability was in favor of pembrolizumab.
